WO1998002149A3 - Use of idebenone and analogues against beta amyloid induced cytotoxicity - Google Patents

Use of idebenone and analogues against beta amyloid induced cytotoxicity Download PDF

Info

Publication number
WO1998002149A3
WO1998002149A3 PCT/JP1997/002391 JP9702391W WO9802149A3 WO 1998002149 A3 WO1998002149 A3 WO 1998002149A3 JP 9702391 W JP9702391 W JP 9702391W WO 9802149 A3 WO9802149 A3 WO 9802149A3
Authority
WO
WIPO (PCT)
Prior art keywords
idebenone
optionally substituted
beta amyloid
induced cytotoxicity
against beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP1997/002391
Other languages
French (fr)
Other versions
WO1998002149A2 (en
Inventor
Masaomi Miyamoto
Keisuke Hirai
Giichi Goto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to EP97930746A priority Critical patent/EP0915696B1/en
Priority to AU34589/97A priority patent/AU3458997A/en
Priority to AT97930746T priority patent/ATE218060T1/en
Priority to US09/180,463 priority patent/US6271266B1/en
Priority to DE69712888T priority patent/DE69712888D1/en
Publication of WO1998002149A2 publication Critical patent/WO1998002149A2/en
Publication of WO1998002149A3 publication Critical patent/WO1998002149A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A compound of the formula:wherein R1 represents a lower alkyl; R2 represents H, an optionally substituted alkyl or an optionally substituted alkenyl; R3 and R4 each represents an optionally substituted lower alkyl or a lower alkoxy, or R3 and R4 form, taken together, an optionally substituted butadienylene; and X1 and X2 each represents an optionally esterified or etherified hydroxy, or a salt thereof is useful for protecting cells from the cytotoxicity of beta-amyloid protein.
PCT/JP1997/002391 1996-07-11 1997-07-10 Use of idebenone and analogues against beta amyloid induced cytotoxicity Ceased WO1998002149A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97930746A EP0915696B1 (en) 1996-07-11 1997-07-10 ANTI-beta-AMYLOID PROTEIN-INDUCED CYTOTOXICITY COMPOSITION
AU34589/97A AU3458997A (en) 1996-07-11 1997-07-10 Anti-beta-amyloid protein-induced cytotoxicity composition
AT97930746T ATE218060T1 (en) 1996-07-11 1997-07-10 COMPOSITIONS THAT PREVENT BETA-AMYLOID PROTEIN RELATED CYTOTOXICITY
US09/180,463 US6271266B1 (en) 1996-07-11 1997-07-10 Use of idebenone and analogues against β amyloid induced cytotoxicity
DE69712888T DE69712888D1 (en) 1996-07-11 1997-07-10 COMPILATIONS THAT PREVENT beta-AMYLOID PROTEIN CONDITIONAL CYTOTOXICITY

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8/182095 1996-07-11
JP18209596 1996-07-11

Publications (2)

Publication Number Publication Date
WO1998002149A2 WO1998002149A2 (en) 1998-01-22
WO1998002149A3 true WO1998002149A3 (en) 1998-06-04

Family

ID=16112269

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1997/002391 Ceased WO1998002149A2 (en) 1996-07-11 1997-07-10 Use of idebenone and analogues against beta amyloid induced cytotoxicity

Country Status (7)

Country Link
US (1) US6271266B1 (en)
EP (1) EP0915696B1 (en)
AT (1) ATE218060T1 (en)
AU (1) AU3458997A (en)
CA (1) CA2252519A1 (en)
DE (1) DE69712888D1 (en)
WO (1) WO1998002149A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2619303T3 (en) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Active redox therapeutic products for the treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
SI1933821T1 (en) * 2005-09-15 2020-11-30 Ptc Therapeutics, Inc. Tail variants of redox-active therapeutics for the treatment of mitochondrial and other diseases and the modulation of energy biomarkers
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
EP1891946A1 (en) * 2006-08-14 2008-02-27 Santhera Pharmaceuticals (Schweiz) AG Transmucosal administration of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone
EA038941B1 (en) 2007-11-06 2021-11-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. 4-(p-QUINONYL)-2-HYDROXYBUTANAMIDE DERIVATIVES FOR TREATMENT OF MITOCHONDRIAL DISEASES
MX363223B (en) 2008-09-10 2019-03-15 Bioelectron Tech Corp Treatment of pervasive developmental disorders with redox-active therapeutics.
US8263094B2 (en) * 2008-09-23 2012-09-11 Eastman Chemical Company Esters of 4,5-disubstituted-oxy-2-methyl-3,6-dioxo-cyclohexa-1,4-dienyl alkyl acids and preparation thereof
DK2605769T3 (en) * 2010-08-16 2016-10-24 Santhera Pharmaceuticals (Schweiz) Ag Benzoquinonderivater for the treatment of mitochondrial diseases of the eye
WO2014035356A1 (en) * 2012-08-31 2014-03-06 Mahmut Bilgic Tablet formulations comprising a quinone derivative active agent
DK3233786T3 (en) 2014-12-16 2022-05-09 Ptc Therapeutics Inc POLYMORPHE AND AMORPHE FORMS OF (R) -2-HYDROXY-2-METHYL-4- (2,4,5-TRIMETHYL-3,6-DIOXOCYCLOHEXA-1,4-DIENYL) BUTANAMIDE
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP7266304B2 (en) 2017-04-21 2023-04-28 ユニヴァーシティー オブ タスマニア Therapeutic compounds and methods
TN2021000075A1 (en) 2018-10-17 2023-01-05 Ptc Therapeutics Inc 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING α-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
MX2024000445A (en) 2021-07-08 2024-04-05 Ptc Therapeutics Inc Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyc lohexa-2,5-diene-1,4-dione.
CN119792259A (en) * 2024-10-14 2025-04-11 中国农业大学 Application of idebenone in the preparation of prion disease drugs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0629400A1 (en) * 1993-06-18 1994-12-21 Takeda Chemical Industries, Ltd. Idebenone compositions for treating Alzheimer's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08768B2 (en) 1989-08-24 1996-01-10 武田薬品工業株式会社 Nerve growth factor secretion inducer
JP2849286B2 (en) * 1992-07-09 1999-01-20 三菱電機株式会社 Method for manufacturing semiconductor device

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0629400A1 (en) * 1993-06-18 1994-12-21 Takeda Chemical Industries, Ltd. Idebenone compositions for treating Alzheimer's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G. WEYER ET AL.: "Efficacy and safety of idebenone in the long-term treatment of Alzheimer's disease: a double-blind, placebo-controlled multicentre study.", HUM. PSYCHOPHARMACOL., vol. 11, no. 1, 1996, pages 53 - 65, XP002047720 *
N.G. RANEN ET AL.: "A controlled trial of idebenone in Huntington's disease.", MOV. DISORD., vol. 11, no. 5, 1996, pages 549 - 554, XP002047721 *
T. NABESHIMA: "Nerve growth factor strategy and preparation of animal model for Alzheimer-type senile dementia.", J. PHARM. SOC. JPN, vol. 115, no. 7, 1995, pages 499 - 512, XP002047725 *
U. SENIN ET AL.: "Idebenone in senile dementia of alzheimer type.", ARCH. GERONTOL. GERIATR., vol. 15, no. 3, 1992, pages 249 - 260, XP002047722 *

Also Published As

Publication number Publication date
CA2252519A1 (en) 1998-01-22
WO1998002149A2 (en) 1998-01-22
US6271266B1 (en) 2001-08-07
EP0915696B1 (en) 2002-05-29
AU3458997A (en) 1998-02-09
DE69712888D1 (en) 2002-07-04
EP0915696A2 (en) 1999-05-19
ATE218060T1 (en) 2002-06-15

Similar Documents

Publication Publication Date Title
WO1998002149A3 (en) Use of idebenone and analogues against beta amyloid induced cytotoxicity
AU8509291A (en) Installation for generating utilizable energy from potential energy
NZ278072A (en) Phenylacetic acid oxime derivatives; biocides
EP1193270A3 (en) Pyrrolobenzodiazepines
MX9603050A (en) 1-h-3-arylpyrrolidine-2,4-dione derivatives as pest-control agents.
GB9607380D0 (en) Synergistic stabilizer mixture
IL126339A (en) Taxol derivatives
AU1537495A (en) Process for the preparation of alkylene glycols
BG101569A (en) Method for sildenaphil preparation
KR100321019B1 (en) A composition comprising a steroid sulphatase inhibitor
AU3740997A (en) Sulfenamide taxane derivatives
FI930632L (en) Connection for adjusting the power of the transmitter amplifier
AU2679595A (en) Improved means of fastening sheets by rivetting
FI963169A0 (en) Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo [c] azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ACE
AU3744397A (en) Total synthesis of antitumor acylfulvenes
AU7915491A (en) Phenyl mercaptotetrazole/tolyltriazole corrosion inhibiting compositions
AU8551191A (en) Inhibition of scale
AU1306595A (en) Comminution with the aid of carbide microspheres
AU1997695A (en) Attachment fitting for wall of flexible structure
MY109144A (en) Benzopyran and related ltb4 antagonists
AU645142B2 (en) Corrosion inhibition
AP9400632A0 (en) Ether derivatives.
AU2881399A (en) N1-modified glycopeptides
EP1074545A4 (en) Isoquinolinesulfonamide derivatives and drugs containing the same as the active ingredient
AU9182098A (en) An arrangement for preventing lifting of adhesively attached fastening materials

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HU IL IS KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2252519

Country of ref document: CA

Ref country code: CA

Ref document number: 2252519

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09180463

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1997930746

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997930746

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997930746

Country of ref document: EP